Agonist and antagonist peptides of carcinoembryonic antigen (cea)
CA 2308127 C · Owner: Schlom, Jeffrey · Inventors: Barzaga, Elene; Zaremba, Sam; Schlom, Jeffrey
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the preparation and use of peptides that act as agonists and antagonists of human carcinoembryonic antigen (CEA). Agonists of the CEA peptide CAP1, are disclosed and their , utility in enhancing immune responses against CEA demonstrated.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 22, 1998 and granted March 22, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 22, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 22, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.